Dr. Thomas William Leblanc, MA, MD

Dr. Leblanc practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Leblanc's NPI, 1790997989, was assigned on May 3, 2007. Dr. Leblanc graduated from Duke University School Of Medicine in 2006. Dr. Leblanc's North Carolina license number on file is 2009-00570.

Dr. Leblanc's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Leblanc's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Leblanc to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leblanc practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Leblanc's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Leblanc is board certified in hospice and palliative medicine by the American Board of Internal Medicine. Dr. Leblanc has a license on file in North Carolina.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Leblanc treats.

CMS data shows 389 Medicare services from Dr. Leblanc across 5 procedure codes in 2024, for 85 Medicare patients. Medicare paid $28,707 for them.

CMS counts 85 Medicare patients who saw Dr. Leblanc in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leblanc's median patient age at 75, with 52% women.

In 2024, Dr. Leblanc wrote 377 Medicare Part D claims for 44 patients. 41% of them were for generic drugs. CMS names the drug for 263 of them, across 14 drugs with 11 or more claims each, at $2,205,053 in total drug cost. In 2023, CMS named 128 claims across 7 drugs.

Dr. Leblanc accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leblanc as offering telehealth.

Dmand AI links 294 papers to Dr. Leblanc, published from 2009 to 2025. 2021 was the busiest year, with 25. The most frequent topics are Palliative Care, Hematologic Neoplasms and Leukemia, Myeloid, Acute. Dr. Leblanc has published most often in Support Care Cancer. Dr. Leblanc's most frequent co-authors are Arif H. Kamal, MD, Jason Allen Webb, MD and Hermioni L. Amonoo, MD.

Dmand AI links Dr. Leblanc to 8 clinical trials. 4 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Multiple Myeloma. Duke University sponsors the most, 4. Open Payments lists research payments to Dr. Leblanc that name 1 trial.

CMS Open Payments shows 1,420 general payments to Dr. Leblanc from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Bristol-Myers Squibb Company paid the most, $488,922. It also lists 56 research payments totaling $154,679 from 2019 to 2025, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. Leblanc.

Dr. Leblanc graduated from Duke University School Of Medicine in 2006. Dr. Leblanc is a member of AOA, AAHPM, ASCO and ASH.

Dr. Leblanc is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.